The Company is utilizing its proprietary 212Pb generator to expand its regional network of drug product finishing facilities, which can improve the capacity for clinical trials and commercial ...

Patients in this cohort are receiving [212Pb]VMT01 at 1.5 mCi as monotherapy. Initial results from the earlier monotherapy cohorts were previously presented at the 21st International Congress of ...